Cargando…
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
BACKGROUND: A combination of S-1 and cisplatin has been shown to be effective with acceptable safety for the first-line treatment of far-advanced gastric cancer in Japan. This is the first randomised phase II trial to compare S-1+paclitaxel with S-1+cisplatin in this setting. METHODS: Patients with...
Autores principales: | Mochiki, E, Ogata, K, Ohno, T, Toyomasu, Y, Haga, N, Fukai, Y, Aihara, R, Ando, H, Uchida, N, Asao, T, Kuwano, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389419/ https://www.ncbi.nlm.nih.gov/pubmed/22617130 http://dx.doi.org/10.1038/bjc.2012.222 |
Ejemplares similares
-
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2006) -
Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans
por: Ohno, Tetsuro, et al.
Publicado: (2011) -
High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients
por: Bai, Tuya, et al.
Publicado: (2017) -
In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012) -
Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer
por: Suzuki, S, et al.
Publicado: (2014)